Catecholamine prodrugs for use in the treatment of Parkinson's disease
AssigneeH. Lundbeck A/S
InventorsMorten Jørgensen, Erhad Ascic, Martin Juhl, Klaus Gjervig Jensen, Ask Püschl, Benny Bang-Andersen
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
Claims23
A compound according to formula (Id)
- or a pharmaceutically acceptable salt thereof,
- wherein R1, R2 and R3 are according to a), b), or c) below:
- a) R1 is substituent (i) below;
- and
- R2 is selected from H, C1-C6 alkyl, benzyl and substituent (i) below;
- and R3 is absent;
- b) R1 is selected from H, C1-C6 alkyl, benzyl and substituent (i) below;
- and
- R2 is substituent (i) below;
- and R3 is absent;
- wherein * indicates the attachment point,
- or
- c) R1 and R2 are both H and R3 is substituent (ii) below, N is positively charged,
- and wherein * indicates the attachment point;
- and wherein
- R4 and R5 are each independently selected from H, C1-C6 alkyl, phenyl, benzyl, C3-C6 cycloalkyl and methyl substituted with C3-C6 cycloalkyl.
A compound which is (4aR,10aR)-7-methoxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ol, or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a therapeutically effective amount of a compound according to formula (Id)
- or a pharmaceutically acceptable salt thereof,
- wherein R1, R2 and R3 are according to a) or b) below:
- a) R1 and R2 are each independently selected from H, C1-C6 alkyl, benzyl and substituent (i) below, and R3 is absent,
- and wherein * indicates the attachment point,
- with the proviso that R1 and R2 cannot both be H;
- or
- b) R1 and R2 are both H and R3 is substituent (ii) below, N is positively charged,
- and wherein * indicates the attachment points;
- and wherein
- R4 and R5 are each independently selected from H, C1-C6 alkyl, phenyl, benzyl, C3-C6 cycloalkyl and methyl substituted with C3-C6 cycloalkyl;
- and one or more pharmaceutically acceptable carriers or diluents.
A method for the treatment of Parkinson's Disease which method comprises the administration of a therapeutically effective amount of a compound according to formula (Id)
- or a pharmaceutically acceptable salt thereof,
- wherein R1, R2 and R3 are according to a) or b) below:
- a) R1 and R2 are each independently selected from H, C1-C6 alkyl, benzyl and substituent (i) below, and R3 is absent,
- and wherein * indicates the attachment point,
- with the proviso that R1 and R2 cannot both be H;
- or
- b) R1 and R2 are both H and R3 is substituent (ii) below, N is positively charged,
- and wherein * indicates the attachment points;
- and wherein
- R4 and R5 are each independently selected from H, C1-C6 alkyl, phenyl, benzyl, C3-C6 cycloalkyl and methyl substituted with C3-C6 cycloalkyl;
- to a patient in need thereof.
Dependencies are inferred from the claim text.